Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis

Area of Science:

• Hepatology
• Nanomedicine
• Oncology

Background:

• Liver metastasis is a major cause of cancer mortality.
• Targeting the liver microenvironment offers a strategy for preventing metastasis.
• MicroRNA-122 (miR-122) is a liver-specific microRNA regulating hepatic functions.

Purpose of the Study:

• To develop a nanoformulation for targeted delivery of miR-122 to hepatocytes.
• To evaluate the efficacy of this nanotherapeutic in preventing colorectal cancer liver metastasis.
• To elucidate the mechanisms underlying the anti-metastatic effects of miR-122 delivery.

Main Methods:

• Engineered a galactose-targeted lipid calcium phosphate (Gal-LCP) nanoformulation encapsulating miR-122.
• Administered Gal-LCP miR-122 to mouse models of colorectal cancer liver metastasis.
• Assessed therapeutic efficacy, toxicity, and molecular/cellular changes in the liver microenvironment.

Main Results:

• Gal-LCP miR-122 demonstrated high specificity and efficiency in delivering miR-122 to hepatocytes with no significant toxicity.
• Treatment effectively prevented liver metastasis and prolonged survival in preclinical models.
• miR-122 delivery downregulated genes in metastatic and inflammatory pathways, including matrix metalloproteinases.
• Treatment increased the CD8+/CD4+ T-cell ratio and reduced immunosuppressive cells, enhancing anti-tumor immunity.

Conclusions:

• Gal-LCP miR-122 is a promising nanotherapeutic for preventing and treating colorectal cancer liver metastasis.
• Targeted delivery of miR-122 modulates the liver microenvironment to inhibit metastasis and promote anti-tumor immunity.
• This strategy highlights the potential of nanomedicine-based miRNA delivery for cancer therapy.